Bavarian Nordic Submits Marketing Authorization Application for its Chikungunya Vaccine Candidate to EMA

Bavarian Nordic Submits Marketing Authorization Application for its Chikungunya Vaccine Candidate to EMA

Bavarian Nordic A/S

Bavarian Nordic A/S

COPENHAGEN, Denmark, June 26, 2024 – Bavarian Nordic A/S (OMX: BAVA) today announced the submission of a Marketing Authorization Application (MAA) to the European Medicines Agency (EMA) seeking approval of the Company’s vaccine candidate for immunization to prevent disease…

[ad_2]

Source link

More From Author

Breakthrough In TB research: IISc team develops 3D system to mimic lung environment

Breakthrough In TB research: IISc team develops 3D system to mimic lung environment

How lifting weights prevents osteoporosis, builds bone density – Deseret News

How lifting weights prevents osteoporosis, builds bone density – Deseret News

Leave a Reply

Your email address will not be published. Required fields are marked *